GlassScriptPhysician profile
John Edward Lloyd
NPI 1740252923
$2,597.39
in general payments reported to CMS, 2019-2025
46 companies · $337 in 2025
The $337 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $242 · 2020: $93.60 · 2021: $321 · 2022: $429 · 2023: $500 · 2024: $673 · 2025: $337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,511.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,511.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $256.61 | 2021-2024 | |
| Novo Nordisk INC | $246.52 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Sumitomo Pharma America, INC. | $239.78 | 2023-2024 | Aptiom, Gemtesa |
| Pfizer INC. | $236.91 | 2019-2025 | |
| Medtronic, INC. | $215.60 | 2023-2024 | Intellis Adaptivestim, Linq II |
| Abbott Laboratories | $111.21 | 2021-2023 | Freestyle Libre 3 |
| Ibsa Pharma INC. | $83.55 | 2021-2022 | |
| Amgen INC. | $82.33 | 2021-2025 | Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $71.85 | 2022 | |
| Amarin Pharma, INC. | $66.94 | 2019-2022 | |
| Lundbeck LLC | $60.28 | 2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $58.12 | 2022-2024 | Nuedexta, Rexulti |
| Astrazeneca Pharmaceuticals LP | $57.83 | 2020-2024 | Airsupra, Farxiga |
| Astellas Pharma US INC | $56.50 | 2019-2023 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $53.54 | 2020-2024 | Dificid |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Lloyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.